RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
SkinBioTherapeutics Stock

SkinBioTherapeutics EBIT 2024

SkinBioTherapeutics EBIT

-2.53 M GBP

Ticker

SBTX.L

ISIN

GB00BF33H870

WKN

A2DPW8

In 2024, SkinBioTherapeutics's EBIT was -2.53 M GBP, a -15.82% increase from the -3 M GBP EBIT recorded in the previous year.

The SkinBioTherapeutics EBIT history

YEAREBIT (undefined GBP)
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-

SkinBioTherapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SkinBioTherapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SkinBioTherapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SkinBioTherapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SkinBioTherapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SkinBioTherapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SkinBioTherapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SkinBioTherapeutics’s growth potential.

SkinBioTherapeutics Revenue, EBIT and net profit per share

DateSkinBioTherapeutics RevenueSkinBioTherapeutics EBITSkinBioTherapeutics Net Income
2025e5.35 M undefined-1.01 M undefined-1.62 M undefined
2024e1.11 M undefined-2.53 M undefined-3.46 M undefined
2023132,060 undefined-3 M undefined-2.84 M undefined
202274,760 undefined-2.98 M undefined-2.79 M undefined
20210 undefined-1.5 M undefined-1.43 M undefined
20200 undefined-1.62 M undefined-1.5 M undefined
20190 undefined-1.36 M undefined-1.15 M undefined
20180 undefined-941,450 undefined-844,420 undefined
20170 undefined-461,220 undefined-645,550 undefined
20160 undefined-4,200 undefined-4,200 undefined

SkinBioTherapeutics stock margins

The SkinBioTherapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SkinBioTherapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SkinBioTherapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SkinBioTherapeutics's sales revenue. A higher gross margin percentage indicates that the SkinBioTherapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SkinBioTherapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SkinBioTherapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SkinBioTherapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SkinBioTherapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SkinBioTherapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SkinBioTherapeutics Margin History

SkinBioTherapeutics Gross marginSkinBioTherapeutics Profit marginSkinBioTherapeutics EBIT marginSkinBioTherapeutics Profit margin
2025e64.51 %-18.87 %-30.17 %
2024e64.51 %-227.27 %-311.51 %
202364.51 %-2,271.2 %-2,146.86 %
202260.65 %-3,988.88 %-3,735.42 %
202164.51 %0 %0 %
202064.51 %0 %0 %
201964.51 %0 %0 %
201864.51 %0 %0 %
201764.51 %0 %0 %
201664.51 %0 %0 %

SkinBioTherapeutics Aktienanalyse

What does SkinBioTherapeutics do?

SkinBioTherapeutics PLC is an innovative biotechnology company specialized in the development of skincare products. The company was founded in 2016 in Manchester, United Kingdom, and has since been led by a team of experienced scientists and entrepreneurs. The company's CEO, Dr. Catherine O'Neill, founded SkinBioTherapeutics PLC with the goal of developing innovative skincare products based on the latest scientific findings. The company focuses on the development of products using probiotic bacteria, which have been found to influence the immune system. SkinBioTherapeutics PLC is divided into three divisions: skincare, medical applications, and cosmetics. The skincare division develops products specifically tailored to the needs of individuals with sensitive and problematic skin, aiming to improve the skin's immune system and reduce inflammation and irritation. The medical applications division focuses on the use of probiotic bacteria in treating skin conditions such as psoriasis, eczema, and acne. The cosmetics division, under the brand "SkinBiotix," develops products to improve skin health and appearance. Currently, SkinBioTherapeutics PLC offers several products, including SkinBiotix Balance, a skincare cream for sensitive and problematic skin, SkinBiotix Cleanse, a gentle water-based cleanser, and SkinBiotix Strengthen, a rich moisturizer for dry and problematic skin. With its unique technology platform and strong emphasis on research and development, SkinBioTherapeutics PLC is well-positioned to continue growing and bringing its innovative products to market. SkinBioTherapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing SkinBioTherapeutics's EBIT

SkinBioTherapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of SkinBioTherapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

SkinBioTherapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in SkinBioTherapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about SkinBioTherapeutics stock

How much did SkinBioTherapeutics achieve in EBIT for the current year?

In the current year, SkinBioTherapeutics has achieved an EBIT of -2.53 M GBP.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company SkinBioTherapeutics.

How has the EBIT of SkinBioTherapeutics developed in recent years?

The EBIT of SkinBioTherapeutics has increased by -15.815% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company SkinBioTherapeutics?

The EBIT of SkinBioTherapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does SkinBioTherapeutics pay?

Over the past 12 months, SkinBioTherapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SkinBioTherapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of SkinBioTherapeutics?

The current dividend yield of SkinBioTherapeutics is .

When does SkinBioTherapeutics pay dividends?

SkinBioTherapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SkinBioTherapeutics?

SkinBioTherapeutics paid dividends every year for the past 0 years.

What is the dividend of SkinBioTherapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is SkinBioTherapeutics located?

SkinBioTherapeutics is assigned to the 'Non-cyclical consumption' sector.

Wann musste ich die Aktien von SkinBioTherapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SkinBioTherapeutics from 12/12/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 12/12/2024.

When did SkinBioTherapeutics pay the last dividend?

The last dividend was paid out on 12/12/2024.

What was the dividend of SkinBioTherapeutics in the year 2023?

In the year 2023, SkinBioTherapeutics distributed 0 GBP as dividends.

In which currency does SkinBioTherapeutics pay out the dividend?

The dividends of SkinBioTherapeutics are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von SkinBioTherapeutics

Our stock analysis for SkinBioTherapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SkinBioTherapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.